Navigation Links
US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
Date:5/26/2011

UPFRONT study.Trials in Progress:Joanne Blum, MD, Texas OncologyPoster #37D

Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive-(ER+) breast cancer.Allen Cohn, MD, Rocky Mountain Cancer CentersLinda DeMarco, MD, FACP, New York Oncology HematologyJean Stephenson, RN, Texas OncologyBrian Ulrich, MD, Texas OncologyPeter Yu, MD, Camino Medical GroupPoster #45F

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 vs gemcitabine alone in previously untreated patients with advanced pancreatic cancer.Frankie Ann Holmes, MD, Texas OncologyPoster #40G

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • A phase 3 trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyPoster #47H

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors.Publish Only:Joyce O'Shaughnessy, MD, Texas Oncology


  • Eribulin mesylate EMBRACE study: Survival analysis excluding patients rechallenged with therapies of the same class.Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology


  • Phase III study of axitinib versus sorafenib for treatment of patients with metastatic renal cell carcinoma.  TRIAL in PROGRESS.William Berry, MD, Cancer Centers of North CarolinaMark Fleming, MD, Virginia Oncology AssociatesMichael Kolodziej, MD, New York Oncology HematologySanjiv Awasthi, Texas OncologyThomas E. Hutson, DO, PharmD, FACP, Texas OncologyDanko Martincic, MD, Cancer Care No
    '/>"/>


  • SOURCE US Oncology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
    3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
    4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
    5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
    6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
    7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
    8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
    9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
    10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
    11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... fixation system for trauma patients. Available in ... ® External Fixation System from Zimmer is a ... materials.   The XtraFix System allows surgeons ... the external fixation process, resulting in saved time, costs and ...
    (Date:3/27/2015)... CHINA AID, the ... Rehabilitation Medicine and Healthcare, second to none in ... held at Shanghai New International Expo Center on 22-24 ... Suggestions on Encouraging Private Capital to Participate in the ... issued by the Ministry of Civil Affairs of ...
    (Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
    Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3
    ... Meaningful Placebo Adjusted Weight,Loss; Obesity Program to ... /PRNewswire-FirstCall/ -- Manhattan,Pharmaceuticals, Inc. today announced results ... of oral Oleoyl-estrone (OE). The results,of both ... and the other in morbid obesity, demonstrated ...
    ... prompt request for meeting with FDA, SEATTLE, ... (CTI) announced today that interim results of,its ... pixantrone is,substituted for doxorubicin in standard CHOP-R ... (NHL), resulted,in essentially all patients on both ...
    Cached Medicine Technology:Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 3Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 4Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 2Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 3Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 4Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 5
    (Date:3/30/2015)... CA (PRWEB) March 30, 2015 Developing ... due to the use of cellular models that recapitulate ... the entirety of the disease. , A company ... human cells to precise specifications has created iPSC-derived ... develop environmentally and genetically driven in vitro models of ...
    (Date:3/29/2015)... (PRWEB) March 30, 2015 At the ... Helo Commercial introduced the new Fonda wall ... Daily. , Club owners and facilities managers with ... the new, sleek design of the Fonda heater. ... the heater is an immediate upgrade for a sauna, ...
    (Date:3/29/2015)... March 30, 2015 Elfster.com, the top-rated ... of its promotional plans to publicize its gift exchange ... holiday season. Known as the leader in Secret Santa ... so that adjacent markets can see the opportunities as ... brand awareness," explained Peter Imburg, CEO of Elster.com. "With ...
    (Date:3/29/2015)... 29, 2015 Adults who are comparing ... nationally on the web can now use the QuotesPros.com ... quotes can now be explored while researching the automated ... Learning the differences between what a term policy provides ... challenge for some men and women. Insurers typically provide ...
    (Date:3/29/2015)... The Claudia Cohen Research Foundation and ... that Dr. Beth Y. Karlan has been selected as ... Prize for Outstanding Gynecologic Researcher. The $50,000 prize is ... Annual Meeting on Women's Cancer in Chicago. , Dr. ... at the Samuel Oschin Comprehensive Cancer Institute and Director ...
    Breaking Medicine News(10 mins):Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:Helo Commercial Introduces Fonda Sauna Heater and Sauna and Steam Continuing Education Program at IHRSA 2Health News:Gift Exchange Generator Promotion Achieves Early Success, Announces Elfster 2Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4
    ... intervention may be more effective, researchers say , , SUNDAY, ... rheumatoid arthritis could be identified and enrolled in clinical ... type of assessment and excluded two traditional assessments, according ... at 292 people, average age 54, seen at the ...
    ... at American Academy of Ophthalmology Annual Meeting Examines ... Glaucoma as Manifestation of a Larger Disease, NEW ORLEANS, ... the eye. For most of the 20th century, it was ... an,increasing number of non-pressure-dependent risk factors have been,identified, suggesting that ...
    ... Showed That Over a 6 Month Period, Nasacort AQ ... Significant Adrenal Suppression in This Same Age ... at,the American College of Allergy, Asthma & Immunology (ACAAI) ... Nasal Spray may be used safely and effectively to ...
    ... factor, study finds, urging greater outreach to bridge racial gap ... from transplant centers doesn,t explain why black Americans with end-stage ... placed on the kidney transplant waiting list, researchers say. ... end-stage renal (kidney) disease patients in Georgia and the Carolinas ...
    ... 9 Four members of the same,family, who ... Medicare Equipment,(DME) companies and Comprehensive Outpatient Rehabilitation Facilities ... for Medicare fraud, Assistant,Attorney General Alice S. Fisher ... Acosta of the Southern District of Florida announced ...
    ... Nov. 9 After several years of litigation,Merck has ... Vioxx. The,medication was pulled off the market in 2004 ... heart attacks and strokes. It is one of the,largest ... Smiljanich is pleased this long process is,coming to a ...
    Cached Medicine News:Health News:New Test Criteria Spots Rheumatoid Arthritis Sooner 2Health News:Looking at Glaucoma as a Systemic Disease 2Health News:Looking at Glaucoma as a Systemic Disease 3Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 2Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 3Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 4Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 5Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 6Health News:Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 2Health News:Four Miami Health Care Company Owners Sentenced to 57 Months in Prison For Medicare Fraud 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: